Sound Shore Management Inc CT Decreases Stake in Zimmer Biomet Holdings, Inc. $ZBH

Sound Shore Management Inc CT trimmed its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 896,284 shares of the medical equipment provider’s stock after selling 30,974 shares during the quarter. Zimmer Biomet accounts for about 2.9% of Sound Shore Management Inc CT’s investment portfolio, making the stock its 11th biggest position. Sound Shore Management Inc CT owned approximately 0.45% of Zimmer Biomet worth $88,284,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Eubel Brady & Suttman Asset Management Inc. raised its position in shares of Zimmer Biomet by 0.5% in the 3rd quarter. Eubel Brady & Suttman Asset Management Inc. now owns 292,749 shares of the medical equipment provider’s stock valued at $28,836,000 after purchasing an additional 1,584 shares in the last quarter. Cibc World Market Inc. raised its position in shares of Zimmer Biomet by 10.4% during the 3rd quarter. Cibc World Market Inc. now owns 19,905 shares of the medical equipment provider’s stock valued at $1,961,000 after acquiring an additional 1,868 shares in the last quarter. Wealthfront Advisers LLC lifted its stake in Zimmer Biomet by 90.1% during the third quarter. Wealthfront Advisers LLC now owns 9,270 shares of the medical equipment provider’s stock worth $913,000 after purchasing an additional 4,393 shares during the last quarter. Key Financial Inc boosted its holdings in Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 163 shares during the period. Finally, Smartleaf Asset Management LLC increased its stake in Zimmer Biomet by 64.1% during the third quarter. Smartleaf Asset Management LLC now owns 1,234 shares of the medical equipment provider’s stock valued at $121,000 after purchasing an additional 482 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Wells Fargo & Company raised their price target on shares of Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Evercore raised shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and boosted their price objective for the company from $94.00 to $120.00 in a research report on Monday, January 5th. UBS Group reissued a “sell” rating and issued a $89.00 target price on shares of Zimmer Biomet in a report on Wednesday. BTIG Research reaffirmed a “buy” rating and set a $112.00 target price on shares of Zimmer Biomet in a report on Tuesday. Finally, Wall Street Zen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $106.45.

Key Zimmer Biomet News

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q4 beat — EPS $2.42 vs. $2.38 consensus and revenue up ~10.9% to ~$2.24B, driven by strong demand for hip and knee devices. Zimmer Biomet beats quarterly estimates on strong hips, knees device demand
• Positive Sentiment: Management announced a new share buyback program alongside the results, which supports earnings per-share and helps explain the stock rally. Zimmer Biomet (ZBH) Is Up 6.1% After Earnings Beat And New Buyback Plan Is Announced
• Positive Sentiment: Some analysts are bullish — BTIG reaffirmed a Buy and a $112 price target, signaling more upside from current levels. Zimmer Biomet (NYSE:ZBH) Earns “Buy” Rating from BTIG Research
• Neutral Sentiment: Several firms raised price targets to ~$98 and kept neutral/equal-weight ratings (Citigroup, Wells Fargo), implying modest upside but not a decisive upgrade. Benzinga
• Neutral Sentiment: Needham reaffirmed a Hold rating, reflecting mixed views on near-term catalysts versus structural demand strength. Needham & Company LLC Reaffirms “Hold” Rating for Zimmer Biomet (NYSE:ZBH)
• Negative Sentiment: Management issued measured FY2026 guidance (adjusted EPS $8.30–$8.45) and warned of headwinds — tariffs and a U.S. salesforce overhaul that could pressure near-term execution and margins. That caution caps upside despite the beat. Zimmer Biomet Holdings Inc (ZBH) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and …
• Negative Sentiment: Margins showed some contraction in the quarter and management commentary flagged operational changes that could delay margin recovery, a potential drag on near-term profitability. Zimmer Biomet tops Q4 expectations but strikes measured tone on 2026 guidance

Zimmer Biomet Stock Up 4.5%

Shares of Zimmer Biomet stock opened at $95.51 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.39. Zimmer Biomet Holdings, Inc. has a 1-year low of $84.59 and a 1-year high of $114.44. The business’s fifty day moving average price is $90.01 and its two-hundred day moving average price is $95.64. The company has a market capitalization of $18.93 billion, a P/E ratio of 26.98, a PEG ratio of 2.34 and a beta of 0.62.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.38 by $0.04. The company had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th were given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date was Tuesday, December 30th. Zimmer Biomet’s payout ratio is 27.12%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.